Stocks Health care ASBP
NASDAQ · Health careAspire Biopharma Holdings, Inc. (ASBP)
It posted a net loss of $11M. At June 30, 2026 it held $12.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Aspire Biopharma Holdings, Inc.
- Net worth
- Aspire Biopharma Holdings, Inc. has a market value (market cap) of $12M at the latest share price, and shareholders' equity of $11.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $6.2K, with a net loss of $24.5M.
- Cash flow
- In fiscal 2025 operations used $4.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aspire Biopharma Holdings, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
What Aspire Biopharma Holdings, Inc. does
Aspire Biopharma Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ASBP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.2K | -$24.5M | -$16.38 | n/a |
| 2024 | n/a | -$1.3M | -$1.90 | n/a |
| 2023 | n/a | $4.5M | n/a | n/a |
| 2022 | n/a | $3.3M | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ASBP ranks in Health care
Latest SEC filings
What Aspire Biopharma Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Auditor change 8-K
- September 9, 2026
- September 8, 2026
- August 19, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was $63.1K; diluted EPS -$1.22 versus -$48.19.
- August 10, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 20, 2026Other event 8-K
Insider trades
What the people running Aspire Biopharma Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns ASBP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lance Friedman13G, passive | 7.92% | August 6, 2026 |
| Gary Shirinyan13G, passive | 7.7% | August 10, 2026 |
| Rubenbauer Alois Ryan III13G, passive | 5% | July 2, 2026 |
Largest institutional holders
Insiders
Questions about ASBP
What does Aspire Biopharma Holdings, Inc. do?
Aspire Biopharma Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as ASBP. Its shares trade on NASDAQ under the ticker ASBP.
What is Aspire Biopharma Holdings, Inc.'s net worth?
Aspire Biopharma Holdings, Inc. has a market value (market cap) of $12M at the latest share price, and shareholders' equity of $11.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aspire Biopharma Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11M.
When did Aspire Biopharma Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the auditor change from September 29, 2026.
When is Aspire Biopharma Holdings, Inc.'s next earnings report?
Aspire Biopharma Holdings, Inc.'s next report was expected around November 11, 2026 and is not on file with the SEC yet.
Similar companies
Compare ASBP with
Follow ASBP
Get an email when Aspire Biopharma Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aspire Biopharma Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.